Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

107
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
107
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

139
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
139
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

298
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
298
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

150
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
150
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

111
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
111
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

89
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
89

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Cardiac-Arterial Coupling After Cardiac Surgery for Aortic Valve Disease.

Reviews in cardiovascular medicine·2026
Same author

Proresolving mediators as cardiovascular biomarkers: solo players or an orchestra?

European heart journal open·2026
Same author

Artificial Intelligence in Biomedical Scientific Publishing.

European heart journal·2026
Same author

Ferroptosis promotes aortic stenosis through 5-lipoxygenase.

European heart journal·2026
Same author

First quinquennium completed: highlights from <i>EHJ Open</i> 2025.

European heart journal open·2026
Same author

Inflammatory and cholesterol risks and rates of major cardiovascular events among patients with atherosclerotic cardiovascular disease in routine care.

European heart journal open·2026

Related Experiment Video

Updated: Nov 5, 2025

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.5K

Fatty acids and aortic valve stenosis.

Oscar Plunde1, Magnus Bäck1

  • 1Translational Cardiology, Center for Molecular Medicine, Department of Medicine Solna, Karolinska Institutet and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.

Kardiologia Polska
|May 18, 2021
PubMed
Summary

Fatty acids may offer new therapeutic targets for aortic valve stenosis (AVS), a condition lacking medical treatments. Understanding their role in resolving inflammation could lead to novel AVS therapies.

Keywords:
calcificationinflammationlipid mediatorsvalvular heart disease

More Related Videos

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

4.3K
Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

8.1K

Related Experiment Videos

Last Updated: Nov 5, 2025

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.5K
Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

4.3K
Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

8.1K

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Inflammation Research

Background:

  • Aortic valve stenosis (AVS) is a debilitating valvulopathy impacting quality of life and longevity, particularly in aging populations.
  • Current medical treatments for AVS are unavailable, highlighting an urgent need for mechanistic insights and therapeutic targets.
  • Obesity and genetic factors related to lipid metabolism and lipoprotein (a) are identified risk factors for AVS.

Purpose of the Study:

  • To review the potential mechanisms by which fatty acids influence the development of aortic valve stenosis.
  • To explore fatty acids as therapeutic targets for AVS by examining their role in inflammation resolution.

Main Methods:

  • Literature review focusing on the role of fatty acids in lipid metabolism, inflammation, and aortic valve calcification.
  • Analysis of current data linking fatty acids to inflammatory processes and macrophage-mediated healing in AVS pathogenesis.

Main Results:

  • AVS progression involves lipid infiltration, inflammation, and oxidative stress, creating a cycle of calcification exacerbated by biomechanical factors.
  • Fatty acids are substrates for lipid mediators crucial in resolving inflammation, potentially counterbalancing AVS-associated inflammatory responses.
  • Fatty acids promote macrophage-mediated healing, contributing to a reduced inflammatory state.

Conclusions:

  • Fatty acids play a significant role in the pathogenesis of aortic valve disease.
  • Targeting fatty acid metabolism and their role in inflammation resolution presents a promising avenue for future AVS therapeutic strategies.